Михаськова Н. С., Кудайбергенова А. Г.

ФГБУ «Научно-исследовательский институт онкологии им. Н. Н. Петрова» Минздрава России; Россия, 197758 Санкт-Петербург, п. Песочный, ул. Ленинградская, 68

1. Breast tumours: WHO classification of tumours. 5th ed. Vol. 2. International Agency for Research on Cancer, 2019. 356 p.

2. Tabár L., Dean P.B., Tucker F.L. et al. Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB. Eur J Radiol 2022;152:110323. DOI: 10.1016/j.ejrad.2022.110323

3. Schedin P., Mitrenga T., McDaniel S., Kaeck M. Mammary ECM composition and function are altered by reproductive state. Mol Carcinog 2004;41(4):207–20. DOI: 10.1002/mc.20058

4. Stirling J.W., Chandler J.A. The fine structure of the normal, resting terminal ductal-lobular unit of the female breast. Virchows Arch A Pathol Anat Histol 1976;372(3):205–26. DOI: 10.1007/BF00433280

5. Wellings S.R., Jensen H.M., Marcum R.G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55(2):231–73.

6. Wellings S.R. A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract 1980;166(4):515–35. DOI: 10.1016/S0344-0338(80)80248-2

7. Rosen P.P. Rosen’s breast pathology. 3rd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2009. Pp. 5–6.

8. Love S.M., Barsky S.H. Anatomy of the nipple and breast ducts revisited. Cancer 2004;101(9):1947–57. DOI: 10.1002/cncr.20559

9. Ramsay D.T., Kent J.C., Hartmann R.A., Hartmann P.E. Anatomy of the lactating human breast redefined with ultrasound imaging. J Anat 2005;206(6):525–34. DOI: 10.1111/j.1469-7580.2005.00417.x

10. Hoda S.A., Brogi E., Koerner F.C., Rosen P.P. Rosen’s breast pathology. 5th ed. Wolters Kluwer, 2020. 1795 p.

11. Russo J., Russo I.H. Development of the human breast. Maturitas 2004;49(1):2–15. DOI: 10.1016/j.maturitas.2004.04.011

12. Tavassoli F.A. Pathology of the breast. 2nd ed. McGraw-Hill Professional, 1999. 669 p.

13. Stirling J.W., Chandler J.A. The fine structure of ducts and subareolar ducts in the resting gland of the female breast. Virchows Arch A Pathol Anat Histol 1977;373(2):119–32. DOI: 10.1007/BF00432157

14. Carter E.P., Gopsill J.A., Gomm J.J. A 3D in vitro model of the human breast duct: a method to unravel myoepithelialluminal interactions in the progression of breast cancer. Breast Cancer Res 2017;19(1):50. DOI: 10.1186/s13058-017-0843-4

15. Boecker W., Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 2003;36(Suppl 1):73–84. DOI: 10.1046/j.1365-2184.36.s.1.7.x

16. Boecker W., van Horn L., Stenman G. Spatially correlated phenotyping reveals K5-positive luminal progenitor cells and p63-K5/14-positive stem cell-like cells in human breast epithelium. Lab Invest 2018;98(8):1065–75. DOI: 10.1038/s41374-018-0054-3

17. Bhargava R., Beriwal S., Dabbs D.J. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127(1):103–13. DOI: 10.1309/TDP92PQLDE2HLEET

18. Chia S.Y., Thike A.A., Cheok P.Y., Tan P.H. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Breast 2010;19(5):355–9. DOI: 10.1016/j.breast.2010.02.007

19. Dekker T.J.A., Ter Borg S., Hooijer G.K.J. et al. Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. Breast Cancer Res Treat 2015;152(2):247–52. DOI: 10.1007/s10549-015-3444-x

20. Kandalaft P.L., Simon R.A., Isacson C., Gown A.M. Comparative sensitivities and specificities of antibodies to breast markers GCDFP-15, Mammaglobin A, and different clones of antibodies to GATA-3: a study of 338 tumors using whole sections. Appl Immunohistochem Mol Morphol 2016;24(9):609–14. DOI: 10.1097/PAI.0000000000000237

21. Liu H., Shi J., Wilkerson M.L., Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 2012;138(1):57–64. DOI: 10.1309/AJCP5UAFMSA9ZQBZ

22. Mazoujian G., Pinkus G.S., Davis S., Haagensen Jr D.E. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983;110(2):105–12.

23. Nakai T., Ichihara S., Kada A. et al. The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers. Virchows Arch 2016;469(2):213–22. DOI: 10.1007/s00428-016-1963-4

24. Reisenbichler E.S., Balmer N.N., Adams A.L. et al. Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction. Mod Pathol 2011;24(2):185–93. DOI: 10.1038/modpathol.2010.197

25. Wick M.R., Lillemoe T.J., Copland G.T. et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alphalactalbumin. Hum Pathol 1989;20(3):281–7. DOI: 10.1016/0046-8177(89)90137-8

26. Liu H. Application of immunohistochemistry in breast pathology: a review and update. Arch Pathol Lab Med 2014;138(12):1629–42. DOI: 10.5858/arpa.2014-0094-RA

27. Pavlakis K., Zoubouli C., Liakakos T. et al. Myoepithelial cell cocktail (p63+SMA) for the evaluation of sclerosing breast lesions. Breast 2006;15(6):705–12. DOI: 10.1016/j.breast.2005.11.005

28. Li A., Ruan M., Fei X. et al. Altered cytokeratin 5 expression in breast lobular myoepithelial cells. J Clin Pathol 2024;77(8):536–43. DOI: 10.1136/jcp-2023-208835

29. Lerwill M.F. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004;28(8):1076–91. DOI: 10.1097/01.pas.0000126780.10029.f0

30. Wang X., Mori I., Tang W. et al. P63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002;9(3):216–9. DOI: 10.1007/BF02967592

31. Seethala R.R., Barnes E.L., Hunt J.L. Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol 2007;31(1):44–57. DOI: 10.1097/01.pas.0000213314.74423.d8

32. Alkhayyat R., Abbas A., Quinn C.M., Rakha E.A. Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls. Histopathology 2024;84(5):723–41. DOI: 10.1111/his.15101

33. Batistatou A., Stefanou D., Arkoumani E., Agnantis N.J. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo 2003;17(6):573–6.

34. Gillett C.E., Bobrow L.G., Millis R.R. S100 protein in human mammary tissue – immunoreactivity in breast carcinoma, including Paget’s disease of the nipple, and value as a marker of myoepithelial cells. J Pathol 1990;160(1):19–24. DOI: 10.1002/path.1711600106

35. Fabris G., Lucantonio A., Hampeet N. et al. Nanoscale topography and poroelastic properties of model tissue breast gland basement membranes. Biophys J 2018;115(9):1770–82. DOI: 10.1016/j.bpj.2018.09.020

36. Yurchenco P.D., Patton B.L. Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Des 2009;15(12):1277–94. DOI: 10.2174/138161209787846766

37. Farahmand S., Cowan D.F. Elastosis in the normal aging breast. A histopathologic study of 140 cases. Arch Pathol Lab Med 1991;115(12):1241–6.

38. Popescu N.C., King C.R., Kraus M.H. Localization of the human erbB- 2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4(3):362–6. DOI: 10.1016/0888-7543(89)90343-1

39. Press M.F., Cordon-Cardo C., Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5(7):953–62.

40. Ross J.S., Fletcher J.A., Bloom K.J. et al. HER-2/neu testing in breast cancer. Am J Clin Pathol 2003;120(Suppl 1):S53–71. DOI: 10.1309/949FPQ1AQ3P0RLC0

41. Ohuchi N. Morphological and immunohistochemical studies of intraductal proliferations of the breast, especially on the carcinogenesis of papilloma and structural atypism of carcinoma. Nippon Geka Gakkai Zasshi 1984;85(11):1393–404.

42. Ohuchi N., Abe R., Kasai M. Possible cancerous change of intraductal papillomas of the breast. A 3D-reconstruction study of 25 cases. Cancer 1984;54(4):605–11. DOI: 10.1002/1097-0142 (1984)54:4<605::aid-cncr2820540402>3.0.co;2-6

43. Tavassoli F.A., Norris H.J. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990;65(3):518–29. DOI: 10.1002/1097-0142(19900201)65:3<518::aidcncr2820650324> 3.0.co;2-o

44. Page D.L., Dupont W.D., Rogers L.W., Rados M.S. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55(11):2698–708. DOI: 10.1002/1097-0142( 19 850601)55:11<2698::aid-cncr2820551127>3.0.co;2-a

45. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974;19(0):331–58. DOI: 10.1016/s0065-230x(08)60058-5